Skip to Content

Eloctate Approval History

  • FDA approved: Yes (First approved June 6th, 2014)
  • Brand name: Eloctate
  • Generic name: antihemophilic factor (recombinant)
  • Dosage form: for Injection
  • Company: Biogen
  • Treatment for: Hemophilia A

Eloctate (antihemophilic factor (recombinant) Fc Fusion Protein is a recombinant DNA derived, antihemophilic factor indicated for the treatment of patients with Hemophilia A.

Development History and FDA Approval Process for Eloctate

DateArticle
Jun  6, 2014Approval FDA Approves Eloctate - first Antihemophilic Factor, Fc Fusion Protein for Patients with Hemophilia A

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide